These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3929596)

  • 1. 1-Deamino-8-D-arginine vasopressin and cryoprecipitate in variant von Willebrand disease.
    Hanna WT; Slywka J; Dent J; Ruggeri ZM; Zimmerman TS
    Am J Hematol; 1985 Oct; 20(2):169-73. PubMed ID: 3929596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryoprecipitate: uses and alternatives.
    Poon MC
    Transfus Med Rev; 1993 Jul; 7(3):180-92. PubMed ID: 8347984
    [No Abstract]   [Full Text] [Related]  

  • 3. DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor.
    Cattaneo M; Moia M; Delle Valle P; Castellana P; Mannucci PM
    Blood; 1989 Nov; 74(6):1972-5. PubMed ID: 2508791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New approach of the treatment of von Willebrand's disease during pregnancy.
    Gojnic M; Fazlagic A; Likic I; Stefanovic A; Vidakovic S; Pervulov M; Petkovic S; Mostic T; Miljic P; Bogdanovic A
    Arch Gynecol Obstet; 2005 Nov; 273(1):35-8. PubMed ID: 16172853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
    Cattaneo M; Simoni L; Gringeri A; Mannucci PM
    Br J Haematol; 1994 Feb; 86(2):333-7. PubMed ID: 8199023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.
    Warrier AI; Lusher JM
    J Pediatr; 1983 Feb; 102(2):228-33. PubMed ID: 6401806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of DDAVP and cryoprecipitate in mild to moderate haemophilia A and von Willebrand's disease.
    Berry EW
    Prog Clin Biol Res; 1990; 324():269-78. PubMed ID: 2106689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DDAVP in acquired von Willebrand syndrome associated with multiple myeloma.
    Takahashi H; Nagayama R; Tanabe Y; Satoh K; Hanano M; Mito M; Shibata A
    Am J Hematol; 1986 Aug; 22(4):421-9. PubMed ID: 3088986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The varieties of von Willebrand's disease.
    Tuddenham EG
    Clin Lab Haematol; 1984; 6(4):307-23. PubMed ID: 6441672
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal fractionated administration of desamino-D-arginine vasopressin (DDAVP) in patients with von Willebrand's disease.
    Garicochea B; D'Amico EA; Bydlowski SP; Chamone DA
    Ann Hematol; 1991; 62(2-3):81-2. PubMed ID: 1903313
    [No Abstract]   [Full Text] [Related]  

  • 12. von Willebrand disease: treatment with or without factor VIII?
    Konkle BA
    J Thromb Haemost; 2007 Jun; 5(6):1113-4. PubMed ID: 17590904
    [No Abstract]   [Full Text] [Related]  

  • 13. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant von Willebrand factor.
    Schwarz HP; Turecek PL; Pichler L; Mitterer A; Mundt W; Dorner F; Roussi J; Drouet L
    Thromb Haemost; 1997 Jul; 78(1):571-6. PubMed ID: 9198218
    [No Abstract]   [Full Text] [Related]  

  • 15. A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH.
    Foster PA
    Thromb Haemost; 1995 Nov; 74(5):1370-8. PubMed ID: 8607125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of patients with hemophilia A and von Willebrand disease to desmopressin (DDAVP).
    Santiago-Borrero PJ; Casanova R
    Bol Asoc Med P R; 1990 May; 82(5):207-10. PubMed ID: 2115785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis of von Willebrand disease and its clinical implications.
    Haematologica; 2004 Sep; 89(9):1036. PubMed ID: 15377463
    [No Abstract]   [Full Text] [Related]  

  • 18. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) infusion in normal subjects.
    Takahashi H; Itoh M; Kobayashi I; Sakuragawa N; Shibata A
    Tohoku J Exp Med; 1980 Oct; 132(2):133-40. PubMed ID: 6777902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and management of von Willebrand's syndrome.
    Rick ME
    Med Clin North Am; 1994 May; 78(3):609-23. PubMed ID: 8170261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.